BRAF and colorectal carcinoma: Most recent National Comprehensive Cancer Network (NCCN) guidelines recommend to evaluate metastatic CRC patients for RAS, mismatch repair, BRAF, HER2, VEGF, and PD-1/PD-L1 status to choose the appropriate initial and subsequent therapy (6).